Multimorbidity and Antiretroviral Therapy Failure: Dose-Response Relationship in a Large Indian Public-Sector Cohort

Nikhil P Hawal; Padmaja R Walavekar; Sonam Bhandurge

doi:10.55489/njcm.170120266013

Authors

Nikhil P Hawal Department of Community medicine, USM KLE International Medical Program, Belagavi, Karnataka, India
Padmaja R Walavekar Department of Community medicine, J.N. Medical College, Belagavi, Karnataka, India
Sonam Bhandurge Department of Computer Sciences, Angadi Institute of Technology and Management, Belagavi, Karnataka, India

DOI:

https://doi.org/10.55489/njcm.170120266013

Keywords:

HIV/AIDS, Antiretroviral Therapy (ART), Multimorbidity, Adherence, HIV Treatment Outcomes

Abstract

Background: The increasing burden of multimorbidity among people living with HIV (PLHIV) threatens the effectiveness of antiretroviral therapy (ART). Very few studies have been published on the predictors of treatment outcome with concurrent medical conditions in resource-poor setting. In this study; we assessed the relationship of multimorbidity with ART failure among HIV-infected adults in Karnataka, India.

Methods: A retrospective study of 2,709 HIV-positive adults started on antiretroviral therapy (ART) from 2019-2023 in a district treatment center in Belgaum. Data gathered were demographic, clinical data like comorbidities (tuberculosis, diabetes and hepatitis B/C) and treatment outcomes. Multivariate logistic regression found independent predictors of treatment failure according to virological, immunological, or clinical definitions.

Results: In total, 542 (19.54%) participants failed treatment. A strong dose-response pattern was observed in treatment failure: 16.3% among patients without comorbidities increased to 22.0% with one co-morbidity condition, 51.6% with two, and 52.0% with all three comorbidities. Tuberculosis showed the highest independent risk (adjusted OR 1.88; 95% CI: 1.44-2.45), and individuals with ≥2 comorbidities had more than double the odds of failure (adjusted OR 2.54; 95% CI: 1.88-3.42). Hepatitis B/C coinfection was also strongly associated with failure (adjusted OR 1.67; 95% CI: 1.11-2.52). Increasing multimorbidity corresponded with poorer CD4 recovery, lower viral suppression, and reduced adherence.

Conclusions: Multimorbidity undermines ART efficacy with a combined impact on immune recovery and treatment adherence. These data support the design of integrated care models for HIV and comorbidities in settings with high burdens. Resource allocation and risk stratification based on the comorbidity burden might be optimized and improve treatment outcomes.

References

UNAIDS. Global HIV & AIDS statistics Fact sheet 2024. Geneva: Joint United Nations Programme on HIV/AIDS; 2024. Available from: https://www.unaids.org/en/resources/fact-sheet [Accessed on December 01, 2025]

Althoff KN, Stewart C, Humes E, Gerace L, Boyd C, Gebo K, Justice AC, . The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. PLoS Med. 2024 Jan 12;21(1):e1004325. DOI: https://doi.org/10.1371/journal.pmed.1004325 PMID: 38215160 PMCID: PMC10833859

Zerihun E, Tesema K, Abera F. Virological treatment failure and associated factors among adults on first-line antiretroviral therapy in West Hararghe, Ethiopia. Front Public Health. 2025 Jun 2;13:1440504. DOI: https://doi.org/10.3389/fpubh.2025.1440504 PMid:40529669 PMCid:PMC12171124

Ross JL, Rupasinghe D, Chanyachukul T, Crabtree Ramírez B, Murenzi G, Kwobah E, et al. Comorbidities and HIV-related factors associated with mental health symptoms and unhealthy substance use among older adults living with HIV in low- and middle-income countries: a cross-sectional study. J Int AIDS Soc. 2025;28(3):e26434. DOI: https://doi.org/10.1002/jia2.26434 PMid:40045453 PMCid:PMC11882396

McCutcheon K, Nqebelele U, Murray L, Thomas TS, Mpanya D, Tsabedze N. Cardiac and Renal Comorbidities in Aging People Living With HIV. Circ Res. 2024 May 24;134(11):1636-1660. DOI: https://doi.org/10.1161/CIRCRESAHA.124.323948 PMid:38781295 PMCid:PMC11122746

Weber MSR, Duran Ramirez JJ, Hentzien M, Cavassini M, Bernasconi E, Hofmann E, et. al; Swiss HIV Cohort Study. Time trends in causes of death in people with HIV: insights from the Swiss HIV Cohort Study. Clin Infect Dis. 2024;79(1):177-188. DOI: https://doi.org/10.1093/cid/ciae014 PMid:38214897 PMCid:PMC11259222

Giri S, Sahu P, Kanungo S, Bal HB, Kumar S, Kar S, Mohanty T, Turuk J, Das D, Hota PK, Pati S. Diabetes mellitus and human immunodeficiency virus (HIV) infection in people with tuberculosis in Odisha, India. Indian J Tuberc. 2024;71(2):147-152. DOI: https://doi.org/10.1016/j.ijtb.2023.04.021 PMid:38589118

World Health Organization. Module 6: Tuberculosis and comorbidities [Internet]. Geneva: World Health Organization; 2024. Available from: https://www.who.int/publications/i/item/9789240087002. [Accessed on December 05, 2025]

Prakoeswa FRS, Maharani F, Bestari RS, et al. Aging and HIV: Recent Findings in Contributing Factors. AIDS Res Treat. 2025 Apr 11;2025:8814760. DOI: https://doi.org/10.1155/arat/8814760 PMID: 40255985 PMCID: PMC12008487

World Health Organization. Fact Sheet: HIV Drug Resistance. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-drug-resistance [Accessed on December 01, 2025]

Ahn MY, Jiamsakul A, Khusuwan S, Khol V, Pham TT, Chaiwarith R, et. Al, The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV. J Int AIDS Soc. 2019 Feb;22(2):e25228. DOI: https://doi.org/10.1002/jia2.25228 PMid:30803162 PMCid:PMC6389354

Assemie MA, Alene M, Ketema DB, Mulatu S. Treatment failure and associated factors among first line patients on highly active antiretroviral therapy in Ethiopia: a systematic review and meta-analysis. Glob Health Res Policy. 2019;4:32. DOI: https://doi.org/10.1186/s41256-019-0120-4 PMid:31687474 PMCid:PMC6820995

Dessie G, Mulugeta H, Wagnew F, Zegeye A, Kiross D, et al. Immunological treatment failure among adult patients receiving highly active antiretroviral therapy in East Africa: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2021;94:100621. DOI: https://doi.org/10.1016/j.curtheres.2020.100621 PMid:34306262 PMCid:PMC8296083

Abie A, Damessa M. The influence of age-associated comorbidities on responses to combination antiretroviral therapy among people living with HIV at the ART clinic of Jimma Medical Center, Ethiopia: A hospital-based nested case-control study. HIV AIDS (Auckl). 2023;15:457-475. DOI: https://doi.org/10.2147/HIV.S421523 PMid:37583543 PMCid:PMC10423692

Hamid S, Badyal A, Sumberia V. Point prevalence of metabolic syndrome in HIV positive patients. J Family Med Prim Care. 2024 Apr;13(4):1328-1332. DOI: https://doi.org/10.4103/jfmpc.jfmpc_1237_23 PMID: 38827683 PMCID: PMC11141984

Sakthivel M, Jayaseelan V, Chinnakali P, Hamide A, Surendran G, Krishnamoorthy Y. Prevalence of Selected Cardiovascular Risk Factors and Their Associated Factors among People Living with HIV/AIDS in India. Indian J Community Med. 2024 Mar-Apr;49(2):308-315. DOI: https://doi.org/10.4103/ijcm.ijcm_583_22 PMID: 38665444 PMCID: PMC11042137

Tiberi S, du Plessis N, Walzl G, Vjecha MJ, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018 Jul;18(7):e183-e198. DOI: https://doi.org/10.1016/S1473-3099(18)30110-5. Erratum in: Lancet Infect Dis. 2018 Jun;18(6):598. DOI: https://doi.org/10.1016/S1473-3099(18)30283-4. PMID: 29580819.

Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson RJ, Lynen L; PredART Trial Team. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med. 2018 Nov 15;379(20):1915-1925. DOI: https://doi.org/10.1056/NEJMoa1800762 PMid:30428290

van Griensven J, Phirum L, Choun K, Thai S, De Weggheleire A, Lynen L. Hepatitis B virus and Hepatitis C virus co-infection among HIV-infected adults on antiretroviral treatment: long-term survival, CD4 cell count recovery and ART-related hepatotoxicity in Cambodia. PLoS One. 2014;9(2):e88552. DOI: https://doi.org/10.1371/journal.pone.0088552 PMid:24533106 PMCid:PMC3922870

Sangeda RZ, Mosha F, Aboud S, Kamuhabwa A, Chalamilla G, Vercauteren J, et al. Predictors of non-adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania. Drug Healthc Patient Saf. 2018;10:79-88. DOI: https://doi.org/10.2147/DHPS.S143178 PMid:30174460 PMCid:PMC6109655

Sukumaran L, Sabin CA. Defining multimorbidity in people with HIV what matters most? Curr Opin HIV AIDS. 2023;18(2):59-67. DOI: https://doi.org/10.1097/COH.0000000000000778 PMid:36655695 PMCid:PMC9894144

McCombe G, Lim J, Van Hout MC, Lazarus JV, Bachmann M, Jaffar S, et al. Integrating Care for Diabetes and Hypertension with HIV Care in Sub-Saharan Africa: A Scoping Review. Int J Integr Care. 2022;22(1):6. DOI: https://doi.org/10.5334/ijic.5839 PMid:35136387 PMCid:PMC8815447